Global Uterotonic Agent Market To Grow At A Rapid CAGR During The Forecast Period

The global uterotonic agent market size was worth around USD 81.47 million in 2022 and is predicted to grow to around USD 156.74 million by 2030 with a compound annual growth rate (CAGR) of roughly 8.52% between 2023 and 2030.

The uterotonic agent market refers to the commercial landscape and other economic activities associated with the production, distribution, and consumption of uterotonic agents. These are pharmaceutical drugs or medicines that are used to induce labor or enhance uterine contractions during childbirth. These are also used to manage certain types of obstetric conditions. The market consists of several types of uterotonic agents which also includes natural compounds and synthetic medicines. They may either be administered using different routes of administration such as intravenous (IV), intramuscular (IM), or oral means. In most cases, the synthetic forms of uterotonic agents such as Pitocin are administered intravenously during labor. This step is undertaken to strengthen contractions. Understanding the market can be beneficial for healthcare providers, pharmaceutical companies, and policymakers to upgrade the systems surrounding the production and distribution of medicines.

This review is based on a report by Zion Market Research, titled "Uterotonic Agent Market By Route Of Administration (Parenteral, Oral, And Others), By Drug (Mifepristone, Carboprost, Dinoprostone, Methylergonovine, And Others), By Distribution Channel (Online Pharmacy, Hospital Pharmacy, And Retail Pharmacy), By Indication (Abortion, Postpartum Hemorrhage, Labor, And Others), And By Region - Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2023 – 2030"- Report at https://www.zionmarketresearch.com/report/uterotonic-agent-market

The global uterotonic agent market is projected to grow owing to the increasing number of childbirth across the globe. As estimated by the United Nations, nearly 385,000 babies are born each day across the globe. The agency estimated that between 2020 and 2070, the number is going to remain stable, which is still a large number of births per day. In addition to this, the rising awareness and initiatives surrounding maternal care especially during childbirth which is one of the leading causes of death in mothers, could also assist in better advertisement and use of uterotonic agents. Healthcare organizations along with aid from the regional government are launching new initiatives that not only promote safe childbirth but also provide necessary tools to ensure the realization of the vision has been of critical importance over the years.

Advancements and developments in medical technology along with better and more informative research has provided medical professionals with higher insights on medicine efficiency and the optimum method of administration which also translated to higher revenue in the uterotonic agent market. Other factors such as increasing focus on women’s health and growth in medical care expenditure are expected to drive the industry further during the forecast period.

The global uterotonic agent industry could face growth restrictions owing to the high cost of medicine. This aspect is especially applicable to economies that are witnessing a resource crunch and lack access to adequate medical care. Additionally, mothers in remote areas may be unaware of the medication and in case of doctor’s negligence, they may suffer from postpartum hemorrhage. There is a serious gap in terms of awareness rate in underdeveloped areas and it greatly impacts the industry growth.

The growing importance of maternal health may provide growth opportunities while the access and distribution challenges could limit market expansion.

The global uterotonic agent market is segmented based on route of administration, drug, distribution channel, indication, and region.

Based on route of administration, the global market segments are parenteral, oral, and others.

Based on drug, the uterotonic agent industry segments are mifepristone, carboprost, dinoprostone, methylergonovine, and others. The most commonly used drug is dinoprostone which is a prostaglandin analog, a synthetic compound that performs actions similar to naturally occurring prostaglandins in the body. The medicine can be administered in several forms such as vaginal suppositories, gels, and inserts. Mifepristone is not typically used as a uterotonic agent. Its main application lies in absorption procedures where it is used in combination with other medicine called misoprostol. Carboprost and methylergonovine are used in more specific situations for instance the former is used to manage postpartum hemorrhage. The Children’s Hospital of Philadelphia claims that around 1 in every 5 women suffer from postpartum hemorrhage.

Based on distribution channel, the global market segments are online pharmacy, hospital pharmacy, and retail pharmacy.

Based on indication, the uterotonic agent industry segments are abortion, postpartum hemorrhage, labor, and others. The highest growth was witnessed in the postpartum segment in 2022. It is also known as PPH and refers to excessive bleeding after childbirth. It is regarded as one of the leading causes of maternal mortality or morbidity worldwide. These agents are essential in stimulating uterine contractions and reducing loss of blood, thus helping in preventing PPH or managing the situation. During labor, medicines help induce the process in case of the absence of natural contractions. They can be used to either initiate the process of strengthening contractions for smooth childbirth. As per the World Health Organization, nearly 223 maternal deaths occurred per 100,000 live births in 2020.

The global uterotonic agent market is projected to witness the highest growth in North America due to the presence of key pharmaceutical players who are investing millions of resources in terms of monetary and non-monetary research and development programs. In 2022 Pfizer Inc., a leading drug maker, spent nearly USD 11.4 billion on research. Furthermore, higher demand for greater quality of medical care and access to the same strengthened by higher disposable income is a leading reason for the region holding dominance in the global market. In Europe, the growth is likely to be driven by excellent health infrastructure and access to medical care. Asia-Pacific is witnessing a surge in birth rates especially in China and India which contributes to the high demand for uterotonic agents. Additionally, the region is witnessing a rise in healthcare expenditure from the government sector which is crucial to regional growth.

Recent Development:

• In April 2023, the West Australian government announced an investment of AUD 1.8 billion to build an advanced maternity hospital on land situated within the precinct of the Fiona Stanley Hospital
• In February 2022, France government announced that the population will have eased access to medication absorption as opposed to invasive surgical procedures

Uterotonic Agent Market: Competitive Analysis

The global uterotonic agent market is led by players like:

• Pfizer Inc.
• Novartis International AG
• Merck & Co. Inc.
• Ferring Pharmaceuticals
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Fresenius Kabi AG
• Bayer AG
• Sanofi S.A.
• Janssen Pharmaceuticals
• Inc. (a subsidiary of Johnson & Johnson)
• Bristol-Myers Squibb Company
• Hikma Pharmaceuticals PLC
• Aspen Pharmacare Holdings Limited
• Sun Pharmaceutical Industries Ltd.
• Lupin Limited
• Torrent Pharmaceuticals Ltd.
• Aurobindo Pharma Limited
• Sandoz International GmbH (a subsidiary of Novartis)
• Zydus Cadila
• Cipla Limited
• Glenmark Pharmaceuticals Ltd.
• Abbott Laboratories. Dr. Reddy's Laboratories Ltd.
• Hologic Inc.
• Lactalis International.

The global uterotonic agent market is segmented as follows:

By Route of Administration

• Parenteral
• Oral
• Others

By Drug

• Mifepristone
• Carboprost
• Dinoprostone
• Methylergonovine
• Others

By Distribution Channel

• Online Pharmacy
• Hospital Pharmacy
• Retail Pharmacy

By Indication

• Abortion
• Postpartum Hemorrhage
• Labor
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of The Middle East & Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com